Pharmakogenetische Tests in der zukünftigen medizinischen Versorgung: Implikationen für Patienten und Ärzte

 

 Buy Article Permissions and Reprints

Zusammenfassung

Ziel: Die Art der Einbindung pharmakogenetischer Untersuchungen in den medizinischen Alltag wird maßgeblich davon beeinflusst werden, ob und unter welchen Rahmenbedingungen Patienten und Ärzte diese akzeptieren. Ein Literatur-Review sollte die Frage beantworten, welche Implikationen und Konsequenzen Patienten und Ärzte bzw. Wissenschaftler bei der Anwendung pharmakogenetischer Untersuchungen erwarten oder vermuten. Methodik: Umfassende Literaturrecherche in MEDLINE (Stichworte: Pharmacogenetics, Delivery of Health Care, Ethics, Attitude, Patient Acceptance of Health Care) nach empirischen und theoretischen Arbeiten, die psychische, familiäre, soziale und ethische Implikationen pharmakogenetischer Untersuchungen beschreiben, um relevante Themen als Grundlage weiterer empirischer Arbeiten zu extrahieren. Ergebnisse und Schlussfolgerungen: Neben antizipierten Vorteilen könnten folgende Faktoren die Akzeptanz pharmakogenetischer Untersuchungen beeinflussen: Erwartung negativer psychosozialer Konsequenzen sowie Sorge um Diskriminierung oder Nichteinhaltung des Datenschutzes. Zudem dürften die Information über Testergebnisse und die Vermittlung der Implikationen pharmakogenetischer Untersuchungen aufgrund ihrer Komplexität eine Herausforderung in der Arzt-Patienten-Beziehung darstellen. Da sich diese Gesichtspunkte vornehmlich aus theoretisch-konzeptionellen Arbeiten ableiten, sind empirische Untersuchungen zur Einstellung von Patienten und Ärzten sowie zum medizinischen und gesundheitsökonomischen Nutzen pharmakogenetischer Untersuchungen dringend erforderlich.

Abstract

Purpose: Since public acceptance of pharmacogenetic testing will largely influence their implementation in routine medical care, common implications of pharmacogenetic testing from patients’, physicians’ and scientists’ perspective are reviewed. Methods: Broad literature review (MEDLINE; MeSH terms: Pharmacogenetics, Delivery of Health Care, Ethics, Attitude, Patient Acceptance of Health Care) of empirical and theoretical studies describing psychological, family-related, social, and ethical consequences of pharmacogenetic testing to describe relevant aspects for further empirical studies. Results: Apart from anticipated benefit, acceptance of pharmacogenetic testing might be influenced by the following: Expectation of negative psychosocial consequences, fear of discrimination or violation of privacy. Due to its great complexity, understanding of test results and explanation of their impact pose new challenges for physician-patient relations. Since most studies are conceptual, empirical studies exploring attitudes of patients/physicians and determining medical as well as economic value of pharmacogenetic testing are imperative.

Literatur

• 1 Evans W E, McLeod H L. Pharmacogenomics - drug disposition, drug targets, and side effects.  N Engl J Med. 2003;  348 538-549
  PubMedGoogle Scholar
• 2 Srivastava P. Drug metabolism and individualized medicine.  Curr Drug Metab. 2003;  4 33-44
  CrossrefPubMedGoogle Scholar
• 3 Schaeffeler E, Fischer C, Brockmeier D. et al . Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants.  Pharmacogenetics. 2004;  14 407-417
  Google Scholar
• 4 Kaskas B A, Louis E, Hindorf U. et al . Safe treatment of thiopurine S-methyltransferase deficient Crohn’s disease patients with azathioprine.  Gut. 2003;  52 140-142
  CrossrefPubMedGoogle Scholar
• 5 Shipkova M, Ahsen N von. Therapie mit Thiopurin-Medikamenten - TDM und Pharmakogenomik der TPMT.  J Lab Med. 2003;  27 211-221
  PubMedGoogle Scholar
• 6 Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase.  Drug Metab Dispos. 2001;  29 601-605
  PubMedGoogle Scholar
• 7 Weinshilboum R. Inheritance and drug response.  N Engl J Med. 2003;  348 529-537
  CrossrefPubMedGoogle Scholar
• 8 West W L, Knight E M, Pradhan S. et al . Interpatient variability: genetic predisposition and other genetic factors.  J Clin Pharmacol. 1997;  37 635-648
  PubMedGoogle Scholar
• 9 Foster M W, Sharp R R, Mulvihill J J. Pharmacogenetics, race, and ethnicity: social identities and individualized medical care.  Ther Drug Monit. 2001;  23 232-238
  CrossrefPubMedGoogle Scholar
• 10 Evans W E. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy.  Ther Drug Monit. 2004;  26 186-191
  PubMedGoogle Scholar
• 11 Aken J van, Schmedders M, Feuerstein G. et al . Prospects and limits of pharmacogenetics: the thiopurine methyl transferase (TPMT) experience.  Am J Pharmacogenomics. 2003;  3 149-155
  PubMedGoogle Scholar
• 12 Williams-Jones B, Corrigan O P. Rhetoric and hype: where’s the ‘ethics’ in pharmacogenomics?.  Am J Pharmacogenomics. 2003;  3 375-383
  PubMedGoogle Scholar
• 13 Nebert D W, Jorge-Nebert L, Vesell E S. Pharmacogenomics and „individualized drug therapy”: high expectations and disappointing achievements.  Am J Pharmacogenomics. 2003;  3 361-370
  PubMedGoogle Scholar
• 14 Goldstein D B. Pharmacogenetics in the laboratory and the clinic.  N Engl J Med. 2003;  348 553-556
  PubMedGoogle Scholar
• 15 Emery J, Hayflick S. The challenge of integrating genetic medicine into primary care.  BMJ. 2001;  322 1027-1030
  CrossrefPubMedGoogle Scholar
• 16 Vaszar L T, Rosen G D, Raffin T A. Pharmacogenomics and the challenge to privacy.  Pharmacogenomics J. 2002;  2 144-147
  CrossrefPubMedGoogle Scholar
• 17 Moldrup C. Ethical, social and legal implications of pharmacogenomics: a critical review.  Community Genet. 2002;  4 204-214
  PubMedGoogle Scholar
• 18 Fears R, Roberts D, Poste G. Rational or rationed medicine? The promise of genetics for improved clinical practice.  BMJ. 2000;  1; 320 933-935
  PubMedGoogle Scholar
• 19 Lichter J B, Kurth J H. The impact of pharmacogenetics on the future of healthcare.  Curr Opin Biotechnol. 1997;  8 692-695
  CrossrefPubMedGoogle Scholar
• 20 Shah J. Criteria influencing the clinical uptake of pharmacogenomic strategies.  BMJ. 2004;  328 1482-1486
  CrossrefPubMedGoogle Scholar
• 21 Tucker G. Pharmacogenetics - expectations and reality.  BMJ. 2004;  329 4-6
  CrossrefPubMedGoogle Scholar
• 22 Melzer D, Detmer D, Zimmern R. Pharmacogenetics and public policy: expert views in Europe and North America.  Pharmacogenomics. 2003;  4 689-691
  CrossrefPubMedGoogle Scholar
• 23 Wertz D C. Ethical, social and legal issues in pharmacogenomics.  Pharmacogenomics J. 2003;  3 194-196
  CrossrefPubMedGoogle Scholar
• 24 Melzer D, Zimmern R. Genetics and medicalisation.  BMJ. 2002;  324 863-864
  CrossrefPubMedGoogle Scholar
• 25 Becquemont L. Clinical relevance of pharmacogenetics.  Drug Metab Rev. 2003;  35 277-285
  CrossrefPubMedGoogle Scholar
• 26 Freund C L, Wilfond B S. Emerging ethical issues in pharmacogenomics: from research to clinical practice.  Am J Pharmacogenomics. 2002;  2 273-281
  PubMedGoogle Scholar
• 27 Knottnerus J A, Weel C van, Muris J W. Evaluation of diagnostic procedures.  BMJ. 2002;  324 477-480
  CrossrefPubMedGoogle Scholar
• 28 Robertson J A, Brody B, Buchanan A. et al . Pharmacogenetic challenges for the health care system.  Health Affairs. 2002;  21 155-167
  PubMedGoogle Scholar
• 29 Kumar S, Gantley M. Tensions between policy makers and general practitioners in implementing new genetics: grounded theory interview study.  BMJ. 1999;  319 1410-1413
  PubMedGoogle Scholar
• 30 Robins R, Metcalfe S. Integrating genetics as practices of primary care.  Soc Sci Med. 2004;  59 223-233
  CrossrefPubMedGoogle Scholar
• 31 Marshall E. Preventing toxicity with a gene test.  Science. 2003;  302 588-590
  CrossrefPubMedGoogle Scholar
• 32 Mountcastle-Shah E, Holtzman N A. Primary care physicians’ perceptions of barriers to genetic testing and their willingness to participate in research.  Am J Med Genet. 2000;  94 409-416
  CrossrefPubMedGoogle Scholar
• 33 Kirchheiner J, Nickchen K, Bauer M. et al . Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.  Mol Psychiatry. 2004;  9 442-473
  CrossrefPubMedGoogle Scholar
• 34 Wolf C R, Smith G, Smith R L. Science, medicine, and the future: Pharmacogenetics.  BMJ. 2000;  320 987-990
  CrossrefPubMedGoogle Scholar
• 35 Weihrauch T R. Pharmakogenetik - Auswirkungen auf die Gesundheitsversorgung und die Gesundheitsökonomie.  Med Klin. 2002;  97 420-428
  CrossrefPubMedGoogle Scholar
• 36 Kirchheiner J, Meisel C, Goldammer M. et al . Pharmakogenetik als Basis neuer Therapiekonzepte.  Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz. 2003;  46 835-844
  PubMedGoogle Scholar
• 37 Roses A D. Pharmacogenetics and the practice of medicine.  Nature. 2000;  405 857-865
  CrossrefPubMedGoogle Scholar
• 38 Ginsburg G S, McCarthy J J. Personalized medicine: revolutionizing drug discovery and patient care.  Trends Biotechnol. 2001;  19 491-496
  CrossrefPubMedGoogle Scholar
• 39 Lash L H, Hines R N, Gonzalez F J. et al . Genetics and susceptibility to toxic chemicals: Do you (or should you) know your genetic profile?.  J Pharmacol Exp Ther. 2003;  305 403-409
  PubMedGoogle Scholar
• 40 Brazell C, Freeman A, Mosteller M. Maximizing the value of medicines by including pharmacogenetic research in drug development and surveillance.  Br J Clin Pharmacol. 2002;  53 224-231
  CrossrefPubMedGoogle Scholar
• 41 Lipton P. Pharmacogenetics: the ethical issues.  Pharmacogenomics J. 2003;  3 14-16
  CrossrefPubMedGoogle Scholar
• 42 Rothstein M A, Epps P G. Pharmacogenomics and the (ir)relevance of race.  Pharmacogenomics J. 2001;  1 104-108
  PubMedGoogle Scholar
• 43 Feuerstein G, Kollek R, Schmedders M. et al . Irreführende Leitbilder - Zum Mythos der Individualisierung durch pharmakogenetische Behandlungskonzepte. Eine kritische Anmerkung.  Ethik Med. 2003;  15 77-86
  CrossrefPubMedGoogle Scholar
• 44 Lee S S. Race, distributive justice and the promise of pharmacogenomics: ethical considerations.  Am J Pharmacogenomics. 2003;  3 385-392
  PubMedGoogle Scholar
• 45 Schmedders M, Aken J van, Feuerstein G. et al . Individualized pharmacogenetic therapy: a critical analysis.  Community Genet. 2003;  6 114-119
  CrossrefPubMedGoogle Scholar
• 46 Evans W E, Relling M V. Pharmacogenomics: translating functional genomics into rational therapeutics.  Science. 1999;  286 487-491
  CrossrefPubMedGoogle Scholar
• 47 Buchanan A, Califano A, Kahn J. et al . Pharmacogenetics: ethical issues and policy options.  Kennedy Inst Ethics J. 2002;  12 1-15
  PubMedGoogle Scholar
• 48 Meisel C, Roots I, Cascorbi I. et al . How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport.  Clin Chem Lab Med. 2000;  38 869-876
  CrossrefPubMedGoogle Scholar
• 49 Johnson J A, Lima J J. Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges.  Pharmacogenetics. 2003;  13 525-534
  PubMedGoogle Scholar
• 50 Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy.  J Intern Med. 2001;  250 186-200
  CrossrefPubMedGoogle Scholar
• 51 Poirier J, Delisle M C, Quirion R. et al . Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease.  Proc Natl Acad Sci U S A. 1995;  92 12 260-12 264
  PubMedGoogle Scholar
• 52 Emilien G, Ponchon M, Caldas C. et al . Impact of genomics on drug discovery and clinical medicine.  QJM. 2000;  93 391-423
  CrossrefPubMedGoogle Scholar
• 53 Evans W E, Johnson J A. Pharmacogenomics: the inherited basis for interindividual differences in drug response.  Annu Rev Genomics Hum Genet. 2001;  2 9-39
  CrossrefPubMedGoogle Scholar
• 54 Thomas S M. Pharmacogenetics: the ethical context.  Pharmacogenomics J. 2001;  1 239-242
  PubMedGoogle Scholar
• 55 Renegar G, Rieser P, Manasco P. Pharmacogenetics: the Rx perspective.  Expert Rev Mol Diagn. 2001;  1 255-263
  CrossrefPubMedGoogle Scholar
• 56 Issa A M. Ethical perspectives on pharmacogenomic profiling in the drug development process.  Nat Rev Drug Discov. 2002;  1 300-308
  CrossrefPubMedGoogle Scholar
• 57 Robertson J A. Consent and privacy in pharmacogenetic testing.  Nat Genet. 2001;  28 207-209
  PubMedGoogle Scholar
• 58 Broadstock M, Michie S, Marteau T. Psychological consequences of predictive genetic testing: a systematic review.  Eur J Hum Genet. 2000;  8 731-738
  CrossrefPubMedGoogle Scholar
• 59 Di Blasi Z, Harkness E, Ernst E. et al . Influence of context effects on health outcomes: a systematic review.  Lancet. 2001;  357 757-762
  CrossrefPubMedGoogle Scholar
• 60 Hapgood R. The potential and limitations of personalised medicine in primary care.  Br J Gen Pract. 2003;  53 915-916
  PubMedGoogle Scholar
• 61 Stamp M J, David S P. Are family physicians willing to use pharmacogenetics for smoking cessation therapy?.  Fam Med. 2003;  35 83
  PubMedGoogle Scholar
• 62 Hoffrage U, Lindsey S, Hertwig R. et al . Communicating statistical information.  Science. 2000;  290 2261-2262
  CrossrefPubMedGoogle Scholar
• 63 Emery J, Kumar S, Smith H. Patient understanding of genetic principles and their expectations of genetic services within the NHS: a qualitative study.  Community Genet. 1998;  1 78-83
  CrossrefPubMedGoogle Scholar
• 64 Emery J. Is informed choice in genetic testing a different breed of informed decision-making? A discussion paper.  Health Expect. 2001;  4 81-86
  CrossrefPubMedGoogle Scholar
• 65 Holtzman N A. Putting the search for genes in perspective.  Int J Health Serv. 2001;  31 445-461
  PubMedGoogle Scholar
• 66 Austin M A, Peyser P A, Khoury M J. The interface of genetics and public health: research and educational challenges.  Annu Rev Public Health. 2000;  21 81-99
  CrossrefPubMedGoogle Scholar
• 67 Gurwitz D, Weizman A, Rehavi M. Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine.  Trends Pharmacol Sci. 2003;  24 122-125
  CrossrefPubMedGoogle Scholar
• 68 Issa A M. Ethical considerations in clinical pharmacogenomics research.  Trends Pharmacol Sci. 2000;  21 247-249
  CrossrefPubMedGoogle Scholar
• 69 March R, Cheeseman K, Doherty M. Pharmacogenetics - legal, ethical and regulatory considerations.  Pharmacogenomics. 2001;  2 317-327
  CrossrefPubMedGoogle Scholar
• 70 Nebert D W, Bingham E. Pharmacogenomics: out of the lab and into the community.  Trends Biotechnol. 2001;  19 519-523
  CrossrefPubMedGoogle Scholar
• 71 McGleenan T, Wiesing U. Versicherung und Genetik - Optionen zur Verhinderung unerwünschter Auswirkungen.  Gesundheitswesen. 2001;  63 583-590
  PubMedGoogle Scholar
• 72 Feuerstein G, Kollek R, Uhlemann T. Gentechnik und Krankenversicherung. Neue Leistungsangebote im Gesundheitssystem. Baden-Baden; Nomos 2002
  Google Scholar
• 73 Alcalde M G, Rothstein M A. Pharmacogenomics: ethical concerns for research and pharmacy practice.  Am J Health Syst Pharm. 2002;  59 2239-2240
  PubMedGoogle Scholar
• 74 Weijer C, Miller P B. Protecting communities in pharmacogenetic and pharmacogenomic research.  Pharmacogenomics J. 2004;  4 (1) 9-16
  PubMedGoogle Scholar
• 75 Meyer T, Vinkemeier U, Meyer U. Ethische Folgeeinschätzung von genotyp-basierten Arzneimitteltherapien.  Dtsch Med Wochenschr. 2002;  127 2524-2526
  Article in Thieme ConnectPubMedGoogle Scholar
• 76 Post S G, Whitehouse P J, Binstock R H. et al . The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective.  JAMA. 1997;  277 832-836
  CrossrefPubMedGoogle Scholar
• 77 Lindpaintner K. Pharmacogenetics and the future of medical practice.  Br J Clin Pharmacol. 2002;  54 221-230
  CrossrefPubMedGoogle Scholar
• 78 Collins F S, Green E D, Guttmacher A E. et al . A vision for the future of genomics research.  Nature. 2003;  422 835-847
  CrossrefPubMedGoogle Scholar
• 79 Paul N W, Roses A D. Pharmacogenetics and pharmacogenomics: recent development, their clinical relevance and some ethical, social and legal implications.  J Mol Med. 2003;  81 135-140
  PubMedGoogle Scholar
• 80 Austin M A. Ethical issues in human genome epidemiology: a case study based on the Japanese American Family Study in Seattle, Washington.  Am J Epidemiol. 2002;  155 585-592
  CrossrefPubMedGoogle Scholar
• 81 Rothenberg K H, Terry S F. Human genetics. Before it’s too late - addressing fear of genetic information.  Science. 2002;  297 196-197
  CrossrefPubMedGoogle Scholar
• 82 Rothstein M A, Epps P G. Ethical and legal implications of pharmacogenomics.  Nat Rev Genet. 2001;  2 228-231
  CrossrefPubMedGoogle Scholar
• 83 Winkelmann B R. Pharmacogenomics, genetic testing and ethnic variability: tackling the ethical questions.  Pharmacogenomics. 2003;  4 531-535
  CrossrefPubMedGoogle Scholar
• 84 Rothstein M A, Hornung C A. Public attitudes about pharmacogenomics. Rothstein MA Pharmacogenomics: Social, ethical, and clinical Dimensions New Jersey; John Wiley 2003: 3-27
  Google Scholar
• 85 Jones J K. Pharmacogenetics and pharmacoepidemiology.  Pharmacoepidemiol Drug Saf. 2001;  10 457-461
  CrossrefPubMedGoogle Scholar
• 86 Anderson D C, Gomez-Mancilla B, Spear B B. et al . Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group.  Pharmacogenomics J. 2002;  2 284-292
  CrossrefPubMedGoogle Scholar
• 87 National Bioethics Advisory Commission (NBAC) . Ethical and Policy Issues in Research Involving Human Participants (Bethesda, Maryland: NBAC 2001). http://www.georgetown.edu/research/nrcbl/nbac/pubs.html. 
  Google Scholar
• 88 Human Genetics Commission .Whose hands on your genes? A discussion document on the storage, protection and use of genetic information. London: Human Genetics Commission, 2000 (http://www.hgc.gov.uk/business_consultations2maintext.pdf). 
  Google Scholar
• 89 Temporary Committee on Human Genetics and Other New Technologies of Modern Medicine . Erice declaration of the ethical principles of pharmacogenetic research. Temporary Committee on Human Genetics and Other New Technologies of Modern Medicine.  Law Hum Genome Rev. 2002;  17 223-228
  PubMedGoogle Scholar
• 90 Brand A. Prädiktive Gentests - Pradigmenwechsel für Prävention und Gesundheitsforschung?.  Gesundheitswesen. 2002;  64 224-229
  Article in Thieme ConnectPubMedGoogle Scholar
• 91 Jallinoja P, Hakonen A, Aro A R. et al . Attitudes towards genetic testing: analysis of contradictions.  Soc Sci Med. 1998;  46 (10) 1367-1374
  CrossrefPubMedGoogle Scholar
• 92 Berth H, Dinkel A, Balck F. Gesundheit durch Gentests? Akzeptanz und Befürchtungen gegenüber genetischen Untersuchungen in einer deutschlandrepräsentativen Stichprobe.  Z Gesundheitspsychol. 2002;  10 97-107
  CrossrefPubMedGoogle Scholar
• 93 Berth H, Balck F, Dinkel A. Attitudes toward genetic testing in patients at risk for HNPCC/FAP and the German population.  Genet Test. 2002;  6 273-280
  CrossrefPubMedGoogle Scholar
• 94 Lipton P. Nuffield Council on Bioethics consultation.  Pharmacogenomics. 2003;  4 91-95
  CrossrefPubMedGoogle Scholar
• 95 Nuffield Council on Bioethics .Pharmacogenetics - ethical issues. Dorchester; The Dorset Press 2003
  Google Scholar
• 96 Paul N, Labisch A. „Health is a crossroad” - Natur und Gesellschaft, Individuum und Gemeinschaft in der öffentlichen Gesundheitssicherung.  Gesundheitswesen. 2002;  64 614-622
  Article in Thieme ConnectPubMedGoogle Scholar

Dipl.-Psych. Anja Rogausch

Abteilung Allgemeinmedizin, Georg-August-Universität Göttingen

Humboldtallee 38

37073 Göttingen

Email: arogaus@gwdg.de